ASTRAZENECA (AZN) Company Report

Analyst Coverage

Research analysts who have asked questions during ASTRAZENECA earnings calls.

Luisa Hector

Berenberg

6 questions for AZN

Also covers: ABBV, BMY, MRK +1 more

Rajan Sharma

Goldman Sachs Group, Inc.

6 questions for AZN

Also covers: ARGX, AUTL, CVAC +6 more

Sachin Jain

Bank of America

6 questions for AZN

Also covers: GMAB, GSK, NVO +2 more

Gonzalo Artiach

Danske Bank

5 questions for AZN

Matthew Weston

UBS Group AG

5 questions for AZN

Also covers: GSK, NVS, SNY

Mattias Häggblom

Handelsbanken

5 questions for AZN

Also covers: GNNDY

Peter Verdult

Citigroup Inc.

5 questions for AZN

Also covers: EVO, GMAB, GRFS +4 more

Seamus Fernandez

Guggenheim Partners

5 questions for AZN

Also covers: AMLX, ARCT, ARQT +9 more

James Gordon

JPMorgan Chase & Co.

4 questions for AZN

Also covers: ARGX, GRFS, GSK

Justin Smith

Bernstein

4 questions for AZN

Also covers: GSK, SCWO

Sarita Kapila

Morgan Stanley

4 questions for AZN

Also covers: GSK, SNY

Simon Baker

Redburn Atlantic

4 questions for AZN

Also covers: AUTL, BNTX, GILD +5 more

Steve Scala

Cowen

4 questions for AZN

Also covers: ABBV, BMY, GSK +6 more

Michael Leuchten

Jefferies

3 questions for AZN

Also covers: GSK, NVO, NVS +1 more

Richard Vosser

JPMorgan Chase & Co.

2 questions for AZN

Also covers: ARGX, MOLN, NVO +2 more

Emily Field

Barclays

1 question for AZN

Also covers: GMAB, GSK, NVO +2 more

Emmanuel Papadakis

Deutsche Bank

1 question for AZN

Also covers: NVO, NVS, SNY

Eric Le Berrigaud

Stifel

1 question for AZN

Also covers: NVS, SNY

Jo Walton

UBS

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Mark Purcell

Morgan Stanley

1 question for AZN

Also covers: GSK, NVS

Peter Welford

Jefferies

1 question for AZN

Also covers: GSK, NVO, NVS +1 more

Rajesh Kumar

HSBC

1 question for AZN

Also covers: BZLFY, LLY, NVO +2 more

Richard Parkes

BNP Paribas Exane

1 question for AZN

Also covers: GSK, NVO, NVS

Timothy Anderson

BofA Securities

1 question for AZN

Also covers: ABBV, AMGN, BIIB +10 more

Latest news

Recent press releases and 8-K filings for AZN.

AstraZeneca's Enhertu Receives Breakthrough Therapy Designation

AZN

Product Launch

New Projects/Investments

AstraZeneca and Daiichi Sankyo's Enhertu has been granted Breakthrough Therapy Designation (BTD) by the US FDA for adult patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant treatment and a high risk of disease recurrence.
This marks the tenth BTD for Enhertu and was based on results from the DESTINY-Breast05 Phase III trial, which demonstrated impressive clinical benefit over the current standard of care.
The BTD is expected to accelerate the development and regulatory review of Enhertu, aiming to provide an important new treatment option to reduce recurrence risk and prevent progression to metastatic disease.

Dec 22, 2025, 12:18 PM

6-K

AstraZeneca's LATIFY Phase III Trial Fails to Meet Primary Endpoint

AZN

The LATIFY Phase III trial of ceralasertib in combination with Imfinzi (durvalumab) did not meet its primary endpoint of overall survival (OS) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
This trial focused on patients whose disease had progressed on or after prior immunotherapy and platinum-based chemotherapy.
The combination of ceralasertib and Imfinzi was generally well tolerated, with a safety profile consistent with the known profiles of each individual medicine and no new safety concerns identified.
AstraZeneca expressed disappointment with the result but affirmed its commitment to pioneering new medicines to improve outcomes for lung cancer patients.

Dec 22, 2025, 12:02 PM

6-K

AstraZeneca's Saphnelo Approved for Subcutaneous Self-Administration in EU

AZN

Product Launch

New Projects/Investments

AstraZeneca's Saphnelo (anifrolumab) has been approved in the European Union (EU) for subcutaneous self-administration as a pre-filled pen for adult patients with systemic lupus erythematosus (SLE).
This approval, based on positive results from the Phase III TULIP-SC trial, offers a convenient subcutaneous option with the potential to reach more patients, providing the same clinical benefits as the Saphnelo IV infusion.
Subcutaneous administration of Saphnelo is currently under regulatory review in several other countries, including the US and Japan.
AstraZeneca will pay Bristol-Myers Squibb (BMS) a low to mid-teens royalty for sales, dependent on geography, under an existing agreement.

Dec 16, 2025, 11:42 AM

6-K

AstraZeneca's Enhertu Receives US Approval for 1st-Line HER2+ Metastatic Breast Cancer

AZN

Product Launch

New Projects/Investments

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in the US for the 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancer.
This approval, based on the DESTINY-Breast09 Phase III trial, demonstrated that Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% compared to THP, achieving a median progression-free survival of 40.7 months versus 26.9 months.
Following this US regulatory approval, AstraZeneca is obligated to pay Daiichi Sankyo a $150 million milestone payment.

Dec 16, 2025, 11:19 AM

6-K

AstraZeneca's Imfinzi Approved for Early Gastric Cancer in US

AZN

Product Launch

AstraZeneca's Imfinzi (durvalumab), in combination with FLOT chemotherapy, has received US approval for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers.
This approval marks Imfinzi as the first and only perioperative immunotherapy for this indication in the US.
The approval is based on MATTERHORN Phase III trial results, demonstrating a 29% reduction in the risk of progression, recurrence or death and a 22% reduction in the risk of death for the Imfinzi regimen compared to chemotherapy alone.
An estimated 69% of patients treated with the Imfinzi-based regimen were alive at three years, compared with 62% in the FLOT-only arm, establishing a new standard of care.

Nov 26, 2025, 11:27 AM

6-K

AstraZeneca's Koselugo Receives US Approval for Adult NF1 Patients

AZN

Product Launch

New Projects/Investments

Alexion, AstraZeneca Rare Disease announced that Koselugo (selumetinib) received US FDA approval for the treatment of adult patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).
This approval was based on positive results from the KOMET Phase III trial, which showed a 20% overall response rate in tumor size reduction for Koselugo, compared to 5% with placebo.
The expanded approval for adults, alongside the recently approved granule formulation for young children, aims to provide continuity of care for NF1 PN patients in the US.

Nov 20, 2025, 1:31 PM

6-K

AstraZeneca PLC Reports Major Holding by The Capital Group Companies, Inc.

AZN

The Capital Group Companies, Inc. notified AstraZeneca PLC of an acquisition of voting rights, crossing a significant ownership threshold.
As of November 13, 2025, The Capital Group Companies, Inc. holds 5.017815% of the voting rights in AstraZeneca PLC, totaling 77,811,893 voting rights.
This represents an increase from their previous notification position of 4.997854%.
The voting rights are held by accounts under the discretionary investment management of Capital Group's investment management companies, rather than for Capital Group's own account.

Nov 17, 2025, 5:52 PM

6-K

AstraZeneca Reports Strong Q3 2025 Growth and Reaffirms Full-Year Guidance

AZN

Earnings

Guidance Update

New Projects/Investments

AstraZeneca reported strong financial results for the first nine months of 2025, with total revenue growing by 11% and core EPS increasing by 15% at constant exchange rates, while reiterating its full-year guidance for high single-digit revenue growth and low double-digit core EPS growth.
The company saw broad-based growth, including a 16% increase in its oncology franchise, and maintained a core operating margin of 33.3%, remaining on track for its mid-30s operating margin target for 2026 and $80 billion revenue ambition for 2030.
AstraZeneca achieved 31 regulatory approvals and positive results from 16 phase three trials in 2025, with key pipeline assets like Baxdrostat and surovatamab having multi-billion dollar peak-year revenue potential, and secured a landmark agreement with the U.S. government providing a three-year exemption from tariffs.

Nov 6, 2025, 1:00 PM

Transcript

AstraZeneca Reports Strong Q3 2025 Performance and Reaffirms Full-Year Guidance

AZN

Earnings

Guidance Update

New Projects/Investments

AstraZeneca reported strong financial performance for the first nine months of 2025, with total revenue growing by 11% and core EPS increasing by 15%. The core operating margin reached 33.3%.
Growth was broad-based, with the oncology franchise up 16%, biopharmaceuticals up 8%, and rare disease up 6%. Revenues in the U.S. and emerging markets outside of China saw increases of 11% and 21%, respectively.
The company achieved 31 regulatory approvals and announced positive results from 16 Phase III trials in 2025, including key readouts for DESTINY-Breast05, DESTINY-Breast11, ROPION-Breast02, BAXC24, and TULIP-SC.
AstraZeneca reiterated its full-year guidance, anticipating total revenue to increase by high single-digit and core EPS by low double-digit % at constant exchange rates. The company remains on track for its 2026 margin target of mid-30s and $80 billion 2030 revenue ambition.
A landmark agreement with the U.S. government provides clarity on pricing and a three-year exemption from tariffs, with the U.S. projected to account for around 50% of total revenue by 2030.

Nov 6, 2025, 1:00 PM

Transcript

AstraZeneca Reports Strong Q3 2025 Performance and Reaffirms Full-Year Guidance

AZN

Earnings

Guidance Update

New Projects/Investments

AstraZeneca reported robust financial results for the first nine months of 2025, with total revenue growing by 11% and core EPS increasing by 15%.
The company reiterated its full-year guidance, anticipating total revenue and core EPS to increase by high single-digit and low double-digit %, respectively, at constant exchange rates.
Key franchises demonstrated strong growth, with Oncology revenue up 16% to $18.6 billion and Biopharmaceuticals revenue up 8% to $17.1 billion in the first nine months.
AstraZeneca remains on track for its 2026 margin target of mid-30s and its $80 billion 2030 revenue ambition, supported by over $10 billion in risk-adjusted peak-year revenue opportunities from 2026 pipeline readouts.
A landmark agreement with the U.S. government provides greater clarity on pricing and a three-year exemption from tariffs, with the U.S. projected to account for around 50% of total revenue by 2030.